Agenus to Participate in Upcoming September Investor Conferences
Business Wire (Mon, 31-Aug 7:30 AM ET)
Business Wire (Fri, 28-Aug 10:07 AM ET)
Business Wire (Wed, 26-Aug 10:05 AM ET)
Agenus Secures $85M Financing to Launch ROBBIN Phase 3 Trial—New Hope for High-Risk Colon Cancer
Market Chameleon (Thu, 6-Aug 4:45 AM ET)
Business Wire (Thu, 6-Aug 7:30 AM ET)
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Business Wire (Tue, 28-Jul 4:30 PM ET)
GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada
PRNewswire (Fri, 24-Jul 6:50 AM ET)
Business Wire (Fri, 17-Jul 10:28 AM ET)
Market Chameleon (Mon, 13-Jul 5:52 AM ET)
Business Wire (Mon, 13-Jul 6:00 AM ET)
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of September 4, 2026, AGEN stock price was flat at $8.24 with 960,634 million shares trading.
AGEN has a beta of 1.00, meaning it tends to be less sensitive to market movements. AGEN has a correlation of 0.02 to the broad based SPY ETF.
AGEN has a market cap of $370.88 million. This is considered a Small Cap stock.
Last quarter Agenus reported $35 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $500,000 and exceeded earnings estimates by $.30.
In the last 3 years, AGEN traded as high as $27.80 and as low as $1.38.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, VXF, VTWO, FDM, IWO.
AGEN has outperformed the market in the last year with a price return of +93.4% while the SPY ETF gained +20.8%. AGEN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +155.9% and +10.0%, respectively, while the SPY returned +2.4% and +1.0%, respectively.
AGEN support price is $7.79 and resistance is $8.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.
